Sarepta's 12% Plunge: A Storm of Revenue Woes and Safety Scrutiny

Summary
• Sarepta (SRPT) plunges 12.42% intraday to $20.87, erasing $3.02 from its opening price of $23.98
• Preliminary Q4 revenue of $369.6M falls short of $380.61M estimates, with Elevidys revenue hit by flu season and rescheduled infusions
• Two patient deaths linked to Elevidys trigger safety concerns, overshadowing $953.8M cash reserves

Sarepta’s stock has imploded on a perfect storm of revenue underperformance and safety red flags. The biotech giant’s preliminary Q4 results revealed a $369.6M net product revenue, missing estimates by $11M, while its flagship gene therapy Elevidys faced operational headwinds and regulatory scrutiny. With the stock trading near its 52-week low of $10.415, the market is now grappling with a critical inflection point for the company’s near-term trajectory.

Elevidys Revenue Woes and Safety Concerns Trigger Sell-Off
Sarepta’s 12.42% intraday collapse stems from a trifecta of challenges: (1) Q4 Elevidys revenue of $110.4M was dented by flu-related rescheduling of six infusions, (2) the company’s full-year 2025 revenue of $1.86B fell $260M short of analyst estimates, and (3) two patient deaths linked to Elevidys—both non-ambulatory patients suffering acute liver failure—sparked safety alarms. CEO Doug Ingram’s admission of 'overcoming challenges in 2025' did little to reassure investors, as the data highlighted operational fragility and regulatory risks. The sell-off reflects a loss of confidence in Elevidys’ commercial durability and the company’s ability to navigate safety hurdles.

Biotech Sector Volatility Amid Regulatory Scrutiny
The broader biotech sector is under pressure, with Amgen (AMGN) down 0.35% as investors reassess risk. However, Sarepta’s 12% drop far outpaces sector peers, underscoring the unique gravity of its Elevidys-related challenges. While Amgen’s decline reflects macroeconomic concerns, Sarepta’s collapse is rooted in product-specific issues—namely, safety liabilities and revenue shortfalls—that could isolate it from sector-wide trends.

Bearish Options Play and Technical Divergence Signal Risk-On Caution
• MACD: 0.596 (above signal line 0.431), RSI: 76.16 (overbought), Bollinger Bands: 20.14–23.59 (price near lower band), 200D MA: $27.74 (price below), Support/Resistance: 18.02–19.24 (key near-term floor)

The technicals paint a bearish divergence: RSI overbought territory and price near Bollinger lower band suggest exhaustion. For options, SRPT20260116C20 and SRPT20260116C20.5 stand out. Both have high leverage (15.23% and 20.71%) and moderate delta (0.64 and 0.56), with implied volatility at 100.71% and 92.03%.

• SRPT20260116C20: Call option with $20 strike, 16% leverage, 182k turnover. High liquidity and moderate delta make it ideal for a 5% downside scenario (targeting $19.83 payoff).
• SRPT20260116C20.5: Call option with $20.5 strike, 20.71% leverage, 6k turnover. Strong gamma (0.177) and theta (-0.177) suggest time decay favors short-term bearish bets.

Aggressive bears should target a breakdown below $20.14 (Bollinger lower band) to trigger a short-term technical cascade. If $19.24 support fails, the 52-week low of $10.415 becomes a critical watchpoint.

Backtest Sarepta Stock Performance
The backtest of SRPT's performance after an intraday plunge of at least -12% from 2022 to the present shows mixed results. The 3-day win rate is 47.70%, the 10-day win rate is 50.10%, and the 30-day win rate is 49.10%. While SRPT has a decent chance of positive returns in the short term, the overall performance is lackluster, with a maximum return of only 0.31% over 30 days.

Sarepta at Crossroads: Safety, Cash, and Strategic Reassessment
Sarepta’s 12% drop signals a pivotal moment. While the company’s $953.8M cash reserves provide liquidity comfort, the Elevidys safety concerns and Q4 revenue shortfall demand urgent operational and regulatory clarity. Investors must watch for a breakdown below $20.14 (Bollinger lower band) or a rebound above $22.35 (30D support). Meanwhile, sector leader Amgen’s -0.35% move highlights broader biotech fragility. For now, the playbook is clear: short-term bears target $19.24 support, while bulls await a rebound above $22.35 to re-enter. The next 72 hours will test Sarepta’s resilience—and its ability to reframe the narrative around Elevidys.